Stroke patients are confronted with hazard on two fronts. First, when a clot blocks blood stream, brain tissue is starved of oxygen and begins to die. Second, when blood flow is restored, parts of the complement system, a part of the innate immune system that protects the physique against pathogens and different invaders, rush in to take away the dead tissue. Antibody-based mostly complement inhibitors patented by MUSC immunologist Stephen Tomlinson, Ph.D., and his collaborators on the University of Colorado have protected towards secondary damage after stroke in preclinical trials by blocking the a part of the complement system that attacks endangered, however salvageable, brain tissue. Tomlinson hopes that one day these complement inhibitors might be given together with tissue plasminogen inhibitor (tPA), the only at the moment accredited therapeutic agent for stroke, to scale back morbidity. Indeed, Tomlinson has proven in a preclinical mannequin that his targeted complement inhibitors could be safely co-administered with tPA and additional can prolong the therapeutic window of protected therapy from three to twelve hours after stroke.
新浪微博
QQ空间
人人网
腾讯微博
Facebook
Google+
Plurk
Twitter
Line